2002

Financing the global response to the epidemic will cost $9.2 billion a year, according to one estimate

11 September 2002. Related: Conference reports, Treatment access.

The Global Fund: what, where, how much?

11 September 2002. Related: Conference reports, Treatment access.

Leading businesses spurn Global Fund

11 September 2002. Related: Conference reports, Treatment access.

14 Caribbean governments sign cut-price drugs agreement with six pharmaceutical companies

11 September 2002. Related: Conference reports, Treatment access.

Thailand offers low-cost transfer to African countries of technology for the local production of generic antiretrovirals

11 September 2002. Related: Conference reports, Treatment access.

Informal market plays a role in distributing antiretrovirals but exposes clients to risks

11 September 2002. Related: Conference reports, Treatment access.

Virus, damned virus, and statistics: the epidemic in numbers

11 September 2002. Related: Other news.

Abacavir hypersensitivity reactions in patients who rechallenge after interruptions for reasons other than hypersensitivity

11 September 2002. Related: Conference reports, Side effects.

Prolonged CNS side-effects of efavirenz can be severe and lead to treatment discontinuation

11 September 2002. Related: Conference reports, Side effects.

Four drug regimen for infants

11 September 2002. Related: Conference reports, Paediatric care.

Study of MTCT programme finds resistance in women on two doses of monotherapy

11 September 2002. Related: Conference reports, Pregnancy, Drug resistance.

Emergence of resistance in children treated with ddI/d4T after treatment to reduce MTCT

11 September 2002. Related: Conference reports, Paediatric care.

Correlates of fatigue in HIV disease

11 September 2002. Related: Conference reports.

Optimum hydroxyurea dose determined

11 September 2002. Related: Conference reports.

Management of people with treatment experience and drug resistance

11 September 2002. Related: Conference reports, Antiretrovirals.

HIV-associated malignancies in the HAART era: flickers of hope and understanding

11 September 2002. Related: Conference reports, Cancer and HIV.

Lopinavir/r exhibits sustained virologic response in antiretroviral-naïve patients: 3-year data

11 September 2002. Related: Conference reports, Antiretrovirals.

Patients will have options regarding T-20 (enfuvirtide) injection sites

11 September 2002. Related: Conference reports, Antiretrovirals.

The role of tenofovir in antiretroviral-naive patients

11 September 2002. Related: Conference reports, Antiretrovirals.

Treatment interruption strategy reports from the XIV International AIDS Conference

11 September 2002. Related: Conference reports, Treatment strategies.

New data from clinical trials of antiretrovirals

11 September 2002. Related: Conference reports, Antiretrovirals.

Behind the headlines about vaccine research

11 September 2002. Related: Conference reports, Vaccines and microbicides.

Trial supports lopinavir/ritonavir as first-line therapy in HIV infection

11 September 2002. Related: Antiretrovirals.

Ritonavir has anti-neoplastic effects independent of HIV inhibition

11 September 2002. Related: Antiretrovirals.

Pharmacokinetics and further benefits of therapeutic drug monitoring (TDM)

11 September 2002. Related: Antiretrovirals.

Antiretroviral use in pregnancy and the risk of an adverse outcome

11 September 2002. Related: Pregnancy.

Triglyceride increase can predict lipodystrophy in HIV patients under highly active antiretroviral therapy

11 September 2002. Related: Side effects, Lipodystrophy and metabolic complications.

Peripheral neuropathy: new data on risk factors, incidence and association with viral load

11 September 2002. Related: Side effects.

High prevalence of osteonecrosis of the hip found in HIV-infection

11 September 2002. Related: Side effects.

Gene discovery offers fresh perspective on HIV/AIDS therapies

11 September 2002. Related: Basic science and immunology.

Growth hormone effective in increasing thymic activity

11 September 2002. Related: Basic science and immunology.

HIV long term nonprogressors have increased immune responsiveness to other viral pathogens

11 September 2002. Related: Basic science and immunology.

Red blood cells new sensitive markers for HIV disease progression?

11 September 2002. Related: Basic science and immunology.

Increased risk of heart abnormalities in children born to mothers with HIV-1

11 September 2002. Related: Paediatric care.

Paclitaxel effective for advanced AIDS-related Kaposi Sarcoma

11 September 2002. Related: Coinfections and complications, Cancer and HIV.

Study finds sexual dysfunction common in HIV-positive men receiving HAART but unrelated to protease inhibitors

11 September 2002. Related: Other news.

ViroLogic announces launch of ‘viral fitness’ assay for HIV infection

11 September 2002. Related: Other news.

Investigations fault HIV/AIDS cure claims

11 September 2002. Related: Cure-related research, Other news.